Prenatal Anti-Müllerian Hormone and PCOS: What the Mouse Study Found

Facebook ↗WhatsApp ↗

Originally published 2018-06-18.

Prenatal Hormone Research and PCOS in a Mouse Model

Zanna Art/Shutterstock

In 2018 a French-led team reported in Nature Medicine that unusually high levels of anti-Müllerian hormone (AMH) during pregnancy could reprogram a developing female fetus and produce polycystic ovary syndrome (PCOS)-like traits in adulthood, at least in mice. The same team then reversed those traits in the mice with a drug already used in IVF. It was an important clue about where PCOS may begin, but it was not a proven cause or a cure for women, and PCOS is still treated today by managing its symptoms.

Here is what the study actually found, why it attracted so much attention, where its limits lie, and what major health bodies say about PCOS now.

What PCOS is and how common it is

PCOS is the most common hormonal disorder in women of reproductive age. The World Health Organization estimates that it affects 10–13% of them, and that up to 70% of affected women have never been diagnosed. Some older articles put the figure as high as one in five; the true number depends on which diagnostic criteria are used, but roughly one in ten is the more widely cited estimate.

Despite the name, PCOS is not really about cysts. The small fluid-filled sacs seen on ultrasound are follicles that stopped developing, and doctors can diagnose PCOS without them. Under the widely used Rotterdam criteria, a diagnosis needs two of three features, once other causes are ruled out:

  • irregular, infrequent or absent periods;
  • signs of high androgens (male-type hormones), such as excess facial or body hair, acne, or raised testosterone in blood tests;
  • polycystic-looking ovaries on ultrasound, or, in newer guidance, a high AMH blood level instead of the scan.

PCOS is the most common cause of anovulation (not releasing an egg) worldwide and a leading cause of infertility. It is also a long-term metabolic condition linked to insulin resistance, type 2 diabetes, high blood pressure, sleep apnoea, endometrial problems, anxiety and depression.

The 2018 study: a hormone in the womb

The research was led by Paolo Giacobini at France's national health research institute, Inserm, in Lille, and published as "Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood" (Tata et al., Nature Medicine, 2018).

AMH is made by cells in small ovarian follicles, and women with PCOS tend to have high levels of it. The team first measured AMH in pregnant women and found it was significantly higher in those with PCOS than in those without; press coverage at the time put the difference at about 30%. Because PCOS often runs in families, the researchers asked whether a mother's hormone levels during pregnancy could help pass the condition to her daughters.

What happened in the mice

To test the idea, they gave pregnant mice extra AMH. Their female offspring grew up with many hallmarks of PCOS: delayed puberty, irregular ovulation, fewer pregnancies and higher testosterone.

The mechanism they proposed runs through the brain. Excess AMH appeared to overstimulate GnRH neurons, the nerve cells that act as the control switch for the reproductive hormone system. In the pregnant mothers this raised testosterone, while less testosterone was converted to oestrogen in the placenta, so the female fetuses were exposed to more male-type hormone than normal. In adulthood, the daughters' GnRH neurons stayed overactive.

Reversing the traits with an IVF drug

The most eye-catching part of the work was the treatment. The team gave adult offspring cetrorelix, a GnRH antagonist that fertility clinics already use to stop eggs being released too early during IVF. Blocking the overactive signal restored a normal hormonal pattern in the mice.

Giacobini told New Scientist that the approach "could be an attractive strategy to restore ovulation and eventually increase the pregnancy rate in these women." Robert Norman of the University of Adelaide, who was not part of the study, called it "a radical new way of thinking about polycystic ovary syndrome."

At the time the team said it hoped to begin a clinical trial in women. A drug that works in mice, however, has a long road before it changes care for people.

Why the headlines went too far

Some coverage in 2018 announced that scientists had found "the cause and cure" of PCOS. That overstated what was shown, for several reasons:

  • Mice are not women. Mice do not develop PCOS naturally, so a mouse model can mimic some features but not the whole human condition.
  • PCOS has many contributors. Twin and family studies point to strong heritability and about two dozen gene regions, while insulin resistance, body weight and other prenatal factors also play a part. Prenatal AMH is likely one route among several, not the single cause.
  • Reversal is not a cure. Normalising hormone levels in adult mice does not show that women would regain regular ovulation safely and lastingly.

The WHO's current fact sheet still states that the exact cause of PCOS is unknown and that there is no cure. A GnRH-antagonist treatment for PCOS is not part of its recommended care.

How PCOS is managed today

Treatment aims to relieve symptoms and reduce long-term risks. According to the WHO and major clinical guidelines, the main options are:

  • Healthy eating and regular activity, recommended for everyone with PCOS. Even modest weight loss of around 5% can improve cycles and metabolic health in women who are overweight.
  • Combined oral contraceptives to regulate periods and reduce acne and unwanted hair; anti-androgen medicines may also help with hair and skin.
  • Metformin, sometimes used for insulin resistance.
  • Fertility treatment, where letrozole is now the usual first choice to trigger ovulation, followed if needed by other medicines, surgery or IVF.
  • Screening for diabetes, cholesterol and blood pressure problems, and attention to mental health.

If you recognise these symptoms or are worried about your fertility, talk to a doctor. Because so many cases go undiagnosed, a simple conversation and a few blood tests can make a real difference.

Why this research still matters

Even without a cure, the 2018 study shifted attention towards the brain and towards pregnancy itself. It suggested that PCOS may begin before birth, which helps explain why it runs in families, and it gave researchers a concrete target in GnRH signalling. It also strengthened the case that AMH is more than a marker of ovarian reserve, which fits with its later use as a diagnostic tool.

The fair summary is this: a promising mechanism in animals, a plausible drug target, and an open question for human trials. For the millions of women living with PCOS today, the most useful steps are still diagnosis, symptom management and care tailored to their goals.

Sources: Tata et al., Nature Medicine 24, 834–846 (2018); World Health Organization: Polycystic ovary syndrome fact sheet; Wikipedia: Polycystic ovary syndrome; New Scientist (original report); IFLScience (original report). Image: Zanna Art/Shutterstock.

COMMENTS